- Page 1: Beyond borders Global biotechnology
- Page 4 and 5: Contents The new normal: the global
- Page 8 and 9: Global introduction The new normal
- Page 10 and 11: Of course, this is not a novel deve
- Page 12 and 13: “Since by definition, increasing
- Page 14 and 15: In both of these models, investors
- Page 16 and 17: “For most of the history of the b
- Page 18 and 19: A closer look Reforming US health c
- Page 20 and 21: Perspectives for the new normal Foc
- Page 22 and 23: Perspectives for the new normal Suc
- Page 24 and 25: John Maraganore of Alnylam Pharmace
- Page 26 and 27: Perspectives for the new normal The
- Page 28 and 29: Using FIPNet to supercharge the inn
- Page 30 and 31: New opportunities 24 Beyond borders
- Page 32 and 33: Conversation on emerging markets Ne
- Page 34 and 35: “The biggest challenge for Wester
- Page 36 and 37: China year in review Accelerating r
- Page 38 and 39: addition, the Government committed
- Page 40 and 41: In 2009, overseas-listed Chinese bi
- Page 42 and 43: India year in review Preparing for
- Page 44 and 45: acquired US-based hybrid sorghum se
- Page 46 and 47: Japanese biotech IPOs, 2009 Company
- Page 48 and 49: drug application for Lurasidone to
- Page 50 and 51: The year saw some examples of globa
- Page 52 and 53: of today’s increasingly pragmatic
- Page 54 and 55: Biotech will provide the technology
- Page 56 and 57:
Malaysia year in review A strategic
- Page 58 and 59:
A transformational year 52 Beyond b
- Page 60 and 61:
Financial performance A transformat
- Page 62 and 63:
explained by developments at a few
- Page 64 and 65:
Selected 2009 US biotechnology publ
- Page 66 and 67:
Growth rate Canada Behind the numbe
- Page 68 and 69:
Australian biotechnology at a glanc
- Page 70 and 71:
Financing A higher bar After a dism
- Page 72 and 73:
the pharmaceutical industry, as pha
- Page 74 and 75:
The final 2009 IPO to close in the
- Page 76 and 77:
The IPO market in Europe remains la
- Page 78 and 79:
Capital raised by Canadian province
- Page 80 and 81:
developed countries — and whether
- Page 82 and 83:
Deals A new landscape Given the rea
- Page 84 and 85:
companies will not make any large u
- Page 86 and 87:
with Elan (the judge agreed) the pa
- Page 88 and 89:
Without Roche-Genentech, the value
- Page 90 and 91:
total potential value of these tran
- Page 92 and 93:
Products and pipeline Steady growth
- Page 94 and 95:
FDA product approvals, 1996-2009 Nu
- Page 96 and 97:
European Phase III pipeline by indi
- Page 98 and 99:
A closer look Uncertain by design:
- Page 100 and 101:
oral anti-diabetes medications Janu
- Page 102 and 103:
Perspectives on personalized medici
- Page 104 and 105:
Moderated by: Gil Forer Ernst & You
- Page 106 and 107:
“I’m starting to see non-tradit
- Page 108 and 109:
from infrastructure funds, but they
- Page 110 and 111:
Data exhibit index 2 The not-quite-
- Page 112 and 113:
Global biotechnology contacts Globa
- Page 114:
Ernst & Young thought leadership Wa